课题基金 / 基金详情

CORE--ADVANCED TECHNOLOGY LABORATORIES

CORE--ADVANCED TECHNOLOGY LABORATORIES
核心--先进技术实验室
批准号:
6099319
负责人:
MARK A JACOBSON
金额:
$15.75万
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
已结题
起止时间:
1999-01-01 至 1999-12-31

项目摘要

项目成果

MARK A JACOBSON的其他基金

相似基金

相关文献

中文摘要
翻译
所有抗感染药物的临床试验均采用微生物 评估化疗剂的体内活性的测试, study. 抗逆转录病毒药物的临床试验也需要类似的试验。 这是UCSF ACTU病毒学核心实验室的目标, 已知或怀疑测量体内抗逆转录病毒作用的试验, 可重现,进行已知或疑似体内测量的试验 抗逆转录病毒的效果,以可重复的,快速和准确的方式。 目前,最广泛用于评估体内抗逆转录病毒的测试 影响是血清HIV p24(核心)抗原,和外周血培养 血液单核细胞检测艾滋病病毒 虽然血清中的变化 p24抗原的浓度似乎是抗逆转录病毒的良好量度 逆转录酶抑制剂的作用,白细胞的简单培养 艾滋病毒没有。 因此,ACTG正在向定量文化发展 作为体内抗逆转录病毒作用的另一个标志物, 检测(例如,PCR扩增后测量HIV cDNA或基因组RNA) 正在考虑。 加州大学旧金山分校ACTU核心病毒学实验室已经 自1987年以来进行HIV培养和p24测定, 自1989年以来连续获得p24抗原检测认证, 文化自1990年以来 此外,我们还在一些 未经认证的程序,如细胞的定量微量培养, 血浆,以及HIV cDNA和基因组RNA的PCR定量。 具体 UCSF ACTU核心病毒学实验室的目标是进行HIV培养, p24抗原定量和ACTU所需的其他病毒学检测 为了以后的测试;通过参加ACTG来保持我们的熟练程度 质量保证计划,并与ACTG在全国范围内合作, 并验证体内抗逆转录病毒作用的其他标志物。
英文摘要
All clinical trials of anti-infective agents have employed microbiologic tests to assess the in vivo activity of the chemotherapeutic agent under study. Similar tests are needed for clinical trails of antiretrovirals. It is the goal of the Virology Core Laboratory of the UCSF ACTU to perform tests known or suspected of measuring in vivo antiretroviral effect in a reproducible, perform tests known or suspected of measuring in vivo antiretroviral effect in a reproducible, rapid and accurate fashion. Currently the tests most widely used for assessing in vivo antiretroviral effect are the serum HIV p24 (core) antigen, and culture of peripheral blood mononuclear cells for HIV. Although changes in the serum concentration of p24 antigen appear to be a good measure of antiretroviral effect with reverse transcriptase inhibitors, simple culture of leukocytes for HIV has not. The ACTG is therefore moving toward quantitative culture of plasma as another marker of in vivo antiretroviral effect, and other tests (e.g. measurement of HIV cDNA or genomic RNA after PCR amplification) are being considered. The UCSF ACTU Core Virology Laboratory has been performing HIV culture and p24 determination since 1987, and has been certified continuously for p24 antigen testing since 1989 and for HIV culture since 1990. In addition, we have experience in some as-yet uncertified procedures such as quantitative microculture of cells and plasma, and PCR quantitation of HIV cDNA and genomic RNA. The specific aims of the UCSF ACTU Core Virology Laboratory are to perform HIV cultures, p24 antigen quantitation, and other virologic testing as needed for ACTU's for later testing; to maintain our proficiency by participating in ACTG quality assurance programs, and to work with the ACTG nationally to develop and validate other markers of in vivo antiretroviral effects.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
HIV Epitope Specific T Cell Responses and Control of HIV Replication
Aberrant T Cell Function and Immunopathogenesis of CMV Immune Recovery Uveitis
HIV Epitope Specific T Cell Responses and Control of HIV Replication
Aberrant T Cell Function and Immunopathogenesis of CMV Immune Recovery Uveitis
海外基金